Ondine Biomedical's phase III LANTERN trial successfully met its primary goal, showing a 41% reduction in surgical site infections within 30 days. The trial involved 5,188 patients across 18 hospitals in the US and Canada, with no significant treatment-related adverse events reported. The treatment uses light-activated nasal disinfection as a non-antibiotic alternative, administered shortly before surgery. Ondine plans to meet with the US FDA to discuss regulatory steps following these positive results.
Grab is in talks to acquire Singapore-based buy-now-pay-later (BNPL) provider Atome Financial, potentially valuing Atome at more than $2 billion. This move aligns with Grab's strategy to grow through acquisitions, following its recent purchases of St...
Nebius still makes up about 25% of Yiannis Zourmpanos' portfolio despite a recent 14% price decline, as he maintains strong confidence in its fundamentals. The Palantir partnership could unlock new revenue streams by leveraging Nebius' AI capacity ac...
Main Street Capital is transitioning from a traditional business development company (BDC) to a synthetic alternative asset manager, supporting its stock trading at a 67% premium to its net asset value (NAV). The company’s portfolio, which includes f...
Sunbelt Rentals Holdings Inc. reported strong double-digit growth in both revenue and net income, driven by strong demand in the equipment rental market. Despite this positive performance and aggressive capital spending along with shareholder returns...
Tribeca Resources has defined multiple high-priority drill targets at its Jiguata copper project in northern Chile, focusing on porphyry and epithermal systems. The 2026 exploration integrated geological, geochemical, and geophysical data to highligh...
